Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06226571 · ClinicalTrials.gov registry record · Phase 1
A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias
A Phase 1 study of Acute Myeloid Leukemias, sponsored by Syndax Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 76
- Enrollment target
- 20
- Study locations
NCT06226571: Recruiting Phase 1 study of Acute Myeloid Leukemias, sponsored by Syndax Pharmaceuticals.
NCT06226571 is a Phase 1 study of Acute Myeloid Leukemias that is actively recruiting participants, run by Syndax Pharmaceuticals. The registered enrollment target is 76 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (27% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06226571, a Phase 1 study of Acute Myeloid Leukemias, is actively recruiting participants, sponsored by Syndax Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 76 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and clinical activity of SNDX-5613 in combination with intensive chemotherapy in participants with newly diagnosed acute myeloid leukemia (AML) harboring alterations in KMT2A, NPM1, or NUP98 genes.
Conditions Studied
Interventions
- DRUG SNDX-5613
- DRUG Chemotherapy Regimen
- DRUG HiDAC
Study Locations (20)
New York
- Institution name: Northwell Health-Brany - Lake Success
- Memorial Sloan Kettering Cancer Center - New York
- University of Rochester Medical Center - Rochester
- SUNY Upstate Medical University - Syracuse
California
- UCLA Medical Hematology - Burbank
- City of Hope Medical Center - Duarte
Florida
- AdventHealth Blood & Marrow Transplant Center - Orlando
- Tampa General Hospital - Tampa
Kentucky
- University of Louisville Health Brown Cancer Center - Louisville
- Norton Cancer Institute, St. Matthews Campus - Louisville
North Carolina
- East Carolina University - Greenville
- Atrium Health Wake Forest Baptist Medical Center - Winston-Salem
Georgia
- Emory Winship Cancer Institute - Atlanta
Illinois
- University of Chicago - Chicago
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2024-05-21 |
| Est. Completion | 2027-02 |
| Phase | Phase 1 |
What NCT06226571 shows while recruiting
NCT06226571 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 76 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (27% higher).
The record links to 1 condition, with Acute Myeloid Leukemias appearing as the primary indexed condition, and to 3 interventions - of which SNDX-5613 is the first listed.
NCT06226571 names 20 study sites across 13 states, led by New York, California, Florida.
Frequently Asked Questions
What is clinical trial NCT06226571 about?
NCT06226571 is a clinical study titled "A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias". The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and clinical activity of SNDX-5613 in combination with intensive chemotherapy in participants with newly diagnosed acute myeloid leukemia (AML) harboring alterations in KMT2A, NPM1, or NUP98 genes.
What is the current status of trial NCT06226571?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 76 participants. The study started on 2024-05-21. Estimated completion is 2027-02.
What conditions does trial NCT06226571 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemias.
What interventions are being tested in trial NCT06226571?
The interventions under investigation include: SNDX-5613 (DRUG), Chemotherapy Regimen (DRUG), HiDAC (DRUG).
Who is sponsoring clinical trial NCT06226571?
This trial is sponsored by Syndax Pharmaceuticals, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06226571 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemias
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06226571's enrollment target sits among peer trials
76 706th of 2000 higher than 1,290 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02615184 · 76 participants · Phase 2
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
- NCT02821741 · 76 participants · NA
Effects of External Ear Stimulation on Pain Perception and Mood
- NCT03019757 · 76 participants
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
- NCT03353584 · 76 participants · NA
Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI